Review of the treatment of metastatic non small cell lung carcinoma: A practical approach

Area of Science:

• Oncology
• Pulmonology
• Pharmacology

Background:

• Growing understanding of non-small cell lung carcinoma (NSCLC) biology.
• Identification of key biomarkers driving NSCLC carcinogenesis and metastasis.
• Recognition of the importance of histological subtypes (squamous vs. non-squamous) in treatment selection.

Purpose of the Study:

• To review current treatment options for metastatic non-small cell lung carcinoma (NSCLC).
• To cover therapies approved in Canada, the United States, or Europe.
• To examine treatments across all lines of therapy.

Main Methods:

• Literature review of approved therapies for metastatic NSCLC.
• Focus on treatments available in North America and Europe.
• Analysis of first-line, second-line, and subsequent treatment options.

Main Results:

• Numerous targeted therapy options are now available for NSCLC patients.
• Histological differentiation is critical for guiding treatment strategies.
• Early integration of palliative care positively impacts patient survival.

Conclusions:

• The landscape of metastatic NSCLC treatment has significantly evolved.
• Personalized treatment approaches based on biomarkers and histology are standard.
• Comprehensive care including palliative support is essential for optimizing outcomes in NSCLC.